Pharmacoeconomic Evaluation of Cancer Biosimilars Worldwide: A Systematic Review

Huang, Huiyao; Liu, Chengcheng; Yu, Yue; Wang, Le; Wu, Dawei; Guo, Lanwei; Wang, Shuhang; Fang, Hong; Bai, Ying; Fang, Yuan; Fan, Qi; Sun, Chao; Wu, Ying; Shi, Jufang; Ma, Fei; Tang, Yu; Dai, Min; Li, Ning

doi:10.3389/fphar.2020.572569

Cited by 13 publications

(6 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Currently, clinical experience with biosimilars exceeds 2 billion patientdays, indicating an increase in global biosimilar adoption [7,10]. A biosimilar is commonly less expensive than the reference biologic, and therefore may increase patient access to effective treatments [10][11][12]. By substituting biosimilars for reference biologics, the cost of high-priced medications used to treat diseases, such as cancer and rheumatoid arthritis (RA), might be reduced by $38.4 billion, or 5.9% of instead to use the term 'biosimilar-to-biosimilar switching' as it is unambiguous and precisely describes the nature of the switch.…”

Section: Key Pointsmentioning

confidence: 99%

Switching from One Biosimilar to Another Biosimilar of the Same Reference Biologic: A Systematic Review of Studies

et al. 2022

View full text Add to dashboard Cite

Background Multiple switches (transitions) between biosimilars of the same reference biologic are now a reality, and they are expected to become more common in the future as more biosimilars enter the market. Switching between two biosimilars of the same reference biologic is generally driven by affordability, formulary requirements, or the relocation/travel of the patient. Evidence of whether switching between biosimilars of the same reference biologic provides similar safety and efficacy profiles is reviewed here. Methods A systematic search was undertaken using electronic databases (to December 2021): Biosis, Embase, MEDLINE, and EBM Reviews/Cochrane Database of Systematic Reviews via Ovid. Publications were evaluated for effectiveness and/ or safety data linked to switching from one biosimilar to another. ResultsThe systematic search yielded 982 citations. After eliminating duplicates, 626 citations remained for the initial title/ abstract screening phase. Following the initial screening, 240 records were chosen; more thorough examination yielded 35 citations. After comprehensive screening and expert advice, 23 studies were selected, of which 13 were published in peerreviewed journals; the remainder have been published as abstracts. Overall, 3657 patients were included in these studies. All studies were observational in nature; no randomized clinical trials were identified. The studies were heterogeneous in size, design, and endpoints. Across the studies, data are provided on safety, effectiveness, immunogenicity, pharmacokinetics, patient retention, patient and physician perceptions, and drug-use patterns. The majority of studies examined switches between biosimilar infliximabs, although switches between biosimilar adalimumabs, etanercepts, and rituximabs were also identified. Two use-pattern studies and one case report were also detected and are discussed. Conclusion Within the limitations of this systematic review, available data suggests that biosimilar-to-biosimilar switching is a safe and effective clinical practice, although it is not covered by current health authority regulations or guidance. No reduction in effectiveness or increase in adverse events was detected in biosimilar-to-biosimilar switching studies conducted to date.

show abstract

Section: Key Pointsmentioning

confidence: 99%

Switching from One Biosimilar to Another Biosimilar of the Same Reference Biologic: A Systematic Review of Studies

et al. 2022

View full text Add to dashboard Cite

show abstract

“…The current RWE corroborates the cost-effectiveness, efficacy, and affordability of oncology biosimilars, such as bevacizumab and trastuzumab biosimilars, from the payer's perspective, while dependent on factors such as uptake rate and price discounts. 63 Efforts should continue to focus on expanding the evidence base to encompass more diverse datasets across the world, and also to consider the long-term cost-effectiveness of oncology biosimilars. 63 However, the potential for cost savings still remains substantial, subject to effective pricing regulation, and well-defined procurement policies for biosimilars.…”

Section: Socioeconomic Implications Of Biosimilars and The Role In On...mentioning

confidence: 99%

“…63 Efforts should continue to focus on expanding the evidence base to encompass more diverse datasets across the world, and also to consider the long-term cost-effectiveness of oncology biosimilars. 63 However, the potential for cost savings still remains substantial, subject to effective pricing regulation, and well-defined procurement policies for biosimilars. 57.60…”

Section: Socioeconomic Implications Of Biosimilars and The Role In On...mentioning

confidence: 99%

Real-World Evidence of Biosimilar Utilisation and Pharmacoeconomics in People Living with Breast or Lung Cancer

Moir

2023

EMJ Oncol

View full text Add to dashboard Cite

As the medical community continues to explore and harness the potential of biosimilars, it is imperative to accumulate robust real-world evidence (RWE) to guide informed decision-making, and enhance patient outcomes in cancer treatment. This article reviews the current understanding and utilisation of biosimilars in the treatment of breast and lung cancers by reviewing existing RWE. A literature search of PubMed, MEDLINE, and Scopus was performed to analyse observational studies pertaining to the adoption of biosimilars in people living with breast or lung cancer, with publications considered since 2019. The review summarises the current RWE relating to biosimilar use for its approved indications across breast and lung cancer. Despite the scarcity of evidence addressing the cost-effectiveness of biosimilars in breast and lung cancer treatment, biosimilars may offer a dual benefit by enhancing patient outcomes, while ensuring cost-effectiveness, thereby increasing access to oncology therapies globally. The increased access to biosimilars within community oncology practices, hospitals, and national healthcare systems, promises substantial cost savings. This review highlights the evolving landscape of biosimilar utilisation in oncology, revealing their potential as a more affordable and inclusive approach to cancer care, while also indicating areas for further research.

show abstract

“…However, the rate of price discount and uptake has largely affected these evidences. 42 Hence, here we are providing a brief overview of some of the recent studies carried out around the globe to provide knowledge of economic impact and financial savings that has been made when biosimilars were implemented in the healthcare sector.…”

Section: Overview Of Economic Impact and Financial Savings From Biosimilar Utilizationmentioning

confidence: 99%

Progress in oncology biosimilars till 2020: Scrutinizing comparative studies of biosimilar monoclonal antibodies

Safdar

Butt

Ahmad

et al. 2021

J Oncol Pharm Pract

View full text Add to dashboard Cite

Stupendous elevation in the healthcare costs has followed with the inception of the current unconventional options of treatment available for cancer patients. There is a dire need of innovative financing approaches to lessen the financial load on healthcare system. Biosimilars are biological drugs consisting of an active ingredient from a reference biological drug that has a great potential of relieving financial load. Strict requirements from regulatory point of view are required as biosimilars are exceedingly similar to but not identical to the reference product. This provides with a certainty that no consequential differences from clinical point of view as compared to the respective biologics exists with regards to efficacy, safety and purity. Safety and effectiveness of biosimilars have been disclosed since more than 10 years of affirmations. However, there is a need to educate the healthcare professionals to abolish potential misconceptions and coalesce biosimilars into regular clinical practice. The present review focuses on providing an overview of regulatory aspects and requirements for biosimilars, the main challenges in the selection and development of biosimilars and the economic impact and financial savings observed in recent studies carried out in different parts of the world. In addition, we have discussed the different successful comparative studies which have been done in different parts of the world to depict the biosimilarity for monoclonal antibodies such as bevacizumab, trastuzumab and rituximab.

show abstract

Pharmacoeconomic Evaluation of Cancer Biosimilars Worldwide: A Systematic Review

Cited by 13 publications

References 37 publications

Switching from One Biosimilar to Another Biosimilar of the Same Reference Biologic: A Systematic Review of Studies

Switching from One Biosimilar to Another Biosimilar of the Same Reference Biologic: A Systematic Review of Studies

Real-World Evidence of Biosimilar Utilisation and Pharmacoeconomics in People Living with Breast or Lung Cancer

Progress in oncology biosimilars till 2020: Scrutinizing comparative studies of biosimilar monoclonal antibodies

Contact Info

Product

Resources

About